CG
ATOS icon

Cutler Group’s Atossa Therapeutics ATOS Stock Holding History

Cutler Group’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38
Closed – – 3589
2023
Q3 		$0 Hold
38
– – ﹤0.01% 3762
2023
Q2 		$0 Hold
38
– – ﹤0.01% 3548
2023
Q1 		$0 Sell
38
-1,311
-97% -$14.6K ﹤0.01% 3769
2022
Q4 		$10K Buy
1,349
+393
+41% +$4.51K ﹤0.01% 2678
2022
Q3 		$11K Buy
956
+836
+697% +$12.1K ﹤0.01% 3046
2022
Q2 		$1K Buy
+120
New +$1.89K ﹤0.01% 4494
2022
Q1 		– Sell
-1,613
Closed -$32.8K – 5292
2021
Q4 		$38K Buy
+1,613
New +$59K ﹤0.01% 2608
2021
Q3 		– Sell
-4,812
Closed -$280K – 5678
2021
Q2 		$456K Buy
4,812
+1,877
+64% +$99.4K 0.02% 802
2021
Q1 		$92K Buy
2,935
+2,875
+4,792% +$105K ﹤0.01% 1843
2020
Q4 		$0 Buy
+60
New +$1.39K ﹤0.01% 4775
2020
Q3 		– Sell
-7
Closed -$336 – 4640
2020
Q2 		$0 Buy
+7
New +$248 ﹤0.01% 4356

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Cutler Group's ATOS Position: Q4 2023 in Review

Cutler Group sold out of Atossa Therapeutics (ATOS) in Q4 2023, closing a stake of 38 shares.

Cutler Group first reported a position in ATOS in Q2 2020 and held it in 11 quarters. The position peaked at $456K in Q2 2021. 49 funds tracked by Wall St. Rank hold ATOS as of Q4 2023.

  • Cutler Group reported no remaining Atossa Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 38 Atossa Therapeutics shares in Q4 2023.
  • Cutler Group first reported a position in Atossa Therapeutics in Q2 2020 and held it in 11 quarters.
  • Cutler Group's Atossa Therapeutics position peaked at $456K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.